Tissue plasminogen activator (tPA)
Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
... (IV) tissue plasminogen activator (tPA) for acute ischaemic stroke (AIS), the concept of using a different dose has been ...IV tPA and gain a better understanding of the impact of ...
7
High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study
... of plasminogen activator inhibitor-1 (PAI-1) were strongly related to the development of diabetes independ- ent from insulin resistance and obesity ...and tissue plasminogen activator ...
7
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
... Stroke) tPA (tissue plasminogen activator) Stroke Study Group published the results of a large multicenter clinical trial demonstrating efficacy of intravenous tPA by revealing a 30% ...
13
Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin A mechanism that slows tPA mediated fibrinolysis but does not require alpha 2 antiplasmin or leakage of intrinsic plasminogen
... extrinsic plasminogen and consequent leaching of clot-bound ...human tissue plasminogen activator (tPA) to fibrin gels resulted in lysis rates that displayed a maximum, with ...
9
Propagating Relationship of Cerebral Oximetric Volume and the Clinical Outcome of Recombinant Tissue Plasminogen Activator (r-TPA) Therapy on Acute Cerebral Ischemic Stroke Patients
... 26. Balucani C, Levine SR, Khoury JC, Khatri P, Saver JL, Broderick JP. Acute ischemic stroke with very early clinical improvement: a national institute of neurological disorders and stroke recombinant tissue ...
8
Alu DNA Polymorphism of Human Tissue Plasminogen Activator (tPA) Gene in Diabetic Jordanian Patients Patients
... Background: Hypercoagulability and hypofibrinolysis are among the symptoms exhibited by diabetic patients. Our study aimed to address the polymorphic nature of Alu DNA fragment in the human tissue ...
6
Structural and kinetic comparison of recombinant human single and two chain tissue plasminogen activator
... single-chain tissue plasminogen activator (sct-PA) and two-chain tissue plasminogen activator (tct-PA), and compared these structural data with measurement of enzymatic ...
8
A Randomized Prospective Assessment of Safety and Effectiveness of Instillation of Tissue Plasminogen Activator in the Management of Intra Abdominal Abscesses
... receive tPA in order to blind the patient and the patient’s primary care physician to the type of treatment the patient was ...the tPA solution was 1 hour prior to reinitia- tion of gravity ...
9
<p>Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion</p>
... the tPA group was significantly thinner than that in the IVB group at the final visit (P = ...the tPA group, and two patients ...the tPA group, two patients underwent vitrec- tomy for an epiretinal ...
10
Thrombus localization with emergency cerebral CT
... Purpose: To determine the prevalence of the hyperdense middle cerebral artery sign HMCAS in an acute stroke population treated with intravenous tissue plasminogen activator tPA within 90[r] ...
7
Intraosseous hemangioma in parietal bone
... baseline; tPA ⫽ tissue plasminogen activator; ICA ⫽ internal carotid artery; MCA ⫽ middle cerebral artery; CTA ⫽ CT angiography; MRA ⫽ MR angiogra- phy; TCD ⫽ transcranial Doppler; cTCD ⫽ ...
7
The American Heart Association’s Get With the Guidelines (GWTG)-Stroke development and impact on stroke care
... AHA/ASA, American Heart Association/American Stroke Association; DTN, door-to-needle; GWTG, Get With the Guidelines; IV TPA, intravenous tissue plasminogen activator; NIHSS, National In[r] ...
12
PHARMACOLOGICAL TREATMENT OF ACUTE ISCHEMIC STROKE: A REVIEW
... preserve tissue in the ischemic penumbra, where perfusion is decreased but sufficient to stave off ...infarction. Tissue in this area of oligemia can be protected by restoring blood flow to the compromised ...
7
Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice – protocol for a cluster randomised controlled trial in acute stroke care
... intravenous tissue plasminogen activator (tPA) administered to ap- propriate patients according to guidelines and within ...intravenous tPA within 6 hours of acute ischaemic stroke ...
13
Central serous chorioretinopathy: a pathogenetic model
... Abstract: Despite numerous studies describing predominantly its demography and clinical course, many aspects of central serous chorioretinopathy (CSCR) remain unclear. Perhaps the major impediment to finding an effective ...
5
Cerebral microbleeds shouldn’t dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage
... The importance of determining the association between CMB and HT after treatment with IV tPA is increasing. Historically, non-contrast head CT has been preferred over MRI in the work-up of acute stroke due to ...
7
noi150075.pdf
... with tPA, only 1 addi- tional sICH occurred compared with those without prior an- tiplatelet ...of tPA likely will outweigh any risk for excess bleeding associated with antiplatelet ...
10
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease
... suPAR, tissue inhibitor of metalloproteinase-1 (TIMP-1), Matrix metalloproteinase-9 (MMP-9), and C-reactive protein (CRP) were detected with Magnetic Luminex Screening ...
8
Tissue-Type Plasminogen Activator, Plasminogen Activator Inhibitor, and Histidine-Rich Glycoproteins in Stressed Human Newborns
... Tissue-type plasminogen activator antigen was determined by an enzyme-linked immuno- sorbent assay (ELISA) method using a commercial kit (Imubind-5- tPA, American Diagnostica).4’9 Plasmi[r] ...
6
The neuroendocrine-like phenotype of gastric myofibroblasts and its significance in cancer.
... normal tissue including, for example, evidence of epigenetic changes in tumour-derived myofibroblasts (Jiang et ...normal tissue (stomach and oesophagus), from inflammatory, non-cancer, tissue ...
224